| Suresh K Joishy, MD | |
|
7300 N Fresno St, Fresno, CA 93720-2941 | |
| (559) 448-4500 | |
| Not Available |
| Full Name | Suresh K Joishy |
|---|---|
| Gender | Male |
| Speciality | Skilled Nursing Facility |
| Location | 7300 N Fresno St, Fresno, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164500070 | NPI | - | NPPES |
| 00C501910 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | C50191 (California) | Secondary |
| 314000000X | Skilled Nursing Facility | MD-18218 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Suresh K Joishy, MD 1800 Harrison St Fl 7, Oakland, CA 94612-3429 Ph: (510) 625-6262 | Suresh K Joishy, MD 7300 N Fresno St, Fresno, CA 93720-2941 Ph: (559) 448-4500 |
News Archive
As the 2010 World Economic Forum on Africa begins Wednesday in Dar Es Salaam, Tanzania, advocates from more than 10 African countries plan to "stage a demonstration" highlighting the need for funding for HIV/AIDS and other diseases, health-e reports (Thom, 5/5).
Use of gemcitabine, a drug that can be effective in treating advanced and resected pancreatic cancer, did not result in improved overall survival after pancreatic cancer resection (surgical removal) compared to patients who received fluorouracil and folinic acid, another treatment regimen that has shown effectiveness, according to a study in the September 8 issue of JAMA.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, today announced it has reached an exclusive distribution agreement with Pulsar Vascular to market and promote that company's PulseRider® in Europe, the Middle East and Africa.
A new study has found for the first time that as Americans are gaining more body fat, so are their babies. The research, which reviewed data from more than 74,000 births, found that a key measure of body fat composition in newborns increased significantly over a 15-year period, mirroring similar increases among pregnant mothers. The findings were presented Sunday by researchers from Children's Mercy Hospitals and Clinics at the Pediatric Academic Societies annual meeting.
NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults.
› Verified 3 days ago